-- Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index decreasing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) fractionally lower.
The iShares Biotechnology ETF (IBB) fell 1.8%.
In corporate news, Grace Therapeutics (GRCE) shares tumbled 48% after it said the US Food and Drug Administration issued a complete response letter for its new drug application for GTx-104, an intravenous formulation of nimodipine for aneurysmal subarachnoid hemorrhage.